The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non–small cell lung cancer: A multicenter retrospective cohort study | Zendy

Yuichiro Takeda | Zendy; Yusaku Kusaba | Zendy; Yoko Tsukita | Zendy; Yukari Uemura | Zendy; Eisaku Miyauchi | Zendy; Takaya Yamamoto | Zendy; Hiroshi Mayahara | Zendy; Akito Hata | Zendy; Hidetsugu Nakayama | Zendy; Satoshi Tanaka | Zendy; Junji Uchida | Zendy; Kazuhiro Usui | Zendy; Tatsuya Toyoda | Zendy; Motohiro Tamiya | Zendy; Masahiro Morimoto | Zendy; Yuko Oya | Zendy; Takeshi Kodaira | Zendy; Keiichi Jingu | Zendy; Hisatoshi Sugiura | Zendy

Open Access

The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non–small cell lung cancer: A multicenter retrospective cohort study

Author(s) -

Yuichiro Takeda,

Yusaku Kusaba,

Yoko Tsukita,

Yukari Uemura,

Eisaku Miyauchi,

Takaya Yamamoto,

Hiroshi Mayahara,

Akito Hata,

Hidetsugu Nakayama,

Satoshi Tanaka,

Junji Uchida,

Kazuhiro Usui,

Tatsuya Toyoda,

Motohiro Tamiya,

Masahiro Morimoto,

Yuko Oya,

Takeshi Kodaira,

Keiichi Jingu,

Hisatoshi Sugiura

Publication year - 2022

Publication title -

clinical and translational radiation oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.336

H-Index - 15

ISSN - 2405-6308

DOI - 10.1016/j.ctro.2022.08.010

Subject(s) - medicine , durvalumab , chemoradiotherapy , radiation therapy , lung cancer , oncology , retrospective cohort study , stage (stratigraphy) , clinical endpoint , proportional hazards model , cancer , surgery , clinical trial , nivolumab , paleontology , immunotherapy , biology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research